Weight-Loss drug semaglutide takes on atrial fibrillation in new trial

NCT ID NCT06499857

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether semaglutide, a medication used for weight loss, can help control atrial fibrillation (AFib) in people who are overweight or have obesity. About 200 adults aged 18-75 with AFib and a BMI of 30 or higher will receive semaglutide plus standard AFib care. Researchers will monitor how long it takes for AFib to return and how much time participants spend in AFib, along with changes in weight and heart fat.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Arizona College of Medicine- Phoenix

    NOT_YET_RECRUITING

    Phoenix, Arizona, 85004, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••